David Cavanagh
Has grant
Senior Lecturer
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
The European Malaria Reagent Repository.
Open Date: 2012-09-03
Close Date: 2017-04-30
Grant: Close
The Edinburgh malaria reagent collections.
Open Date: 2011-09-19
Close Date: 2012-09-18
Grant: Close
Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation
Open Date: 2009-04-01
Close Date: 2012-03-31
Grant: Close
The Tetrahymena system as an innovative approach to malaria vaccine antigen expression
Open Date: 2007-01-01
Close Date: 2010-06-30
Grant: Close
The European malaria vaccine development association
Open Date: 2006-12-01
Close Date: 2012-05-31
Articles (2)
Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogen’s proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 – 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers.
Year:
2024
Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogen’s proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 – 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers.
Year:
2024
Collaborators (10)
Susanna Dunachie
Professor at University of Oxford
University of Oxford
Patrick Kearns
ECAT/Wellcome Trust Clinical Lecturer
University of Edinburgh
Julian Knight
University of Oxford
Teresa Lambe
University of Oxford
Joseph Marsh
University of Edinburgh
Nick Gilbert
Principal Investigator
University of Edinburgh
Tracy Hussell
The University of Manchester
Alexander Mentzer
Principal Investigator / Clinical Research Scientist
University of Oxford
Susan Rosser
Professor of Synthetic Biology
University of Edinburgh
Madhvi Menon
The University of Manchester
Make your next move.
Prepare your application
Review drafts before you send them.